EverQuote reported a 25% year-over-year revenue increase to $218.1 million in Q3 2026, driven by strong growth in automotive and home insurance verticals. Adjusted EBITDA surged 41% to $35.5 million, while net income was $18.2 million despite higher taxes and a one-time charge. The company ended the quarter with $229.1 million cash, no debt, and announced a $50 million share buyback program. EverQuote projects continued momentum in Q4 with revenue guidance of $213-$223 million and adjusted EBITDA of $29-$32 million, highlighting confidence in its AI-driven insurance growth solutions.
EverQuote reported a 25% year-over-year revenue increase to $218.1 million in Q3 2026. For readers following the Financials sector, here is Pluang's market snapshot as of Nov 03, 2026 03:21 WIB: out of 142 priced US Financials stocks, 113 rose and 29 fell. Notable movers include UPST at USD 21.52 with a 1-day change of -6.52% and 100% buy order activity, CLSK at USD 7.22 down 5.68% with 100% buy order activity, and BN at USD 41.42 up 5.45% with 100% sell order activity.
Zentalis Pharmaceuticals awarded 136,000 non-qualified stock options to four newly hired employees as an inducement to join the company, under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.85, matching the stock's closing p...
Dianthus Therapeutics, a clinical-stage biotech company, granted stock options to three new non-executive employees as inducements for joining the company. The options cover 26,000 shares at an exercise price of $82.25, vesting over four years. This ...
The Federal Home Loan Bank of Atlanta announced the election of three new member directors and the re-election of one independent director to its board for 2026. Suzanne DeFerie was named Chair and Kathy McKinney Vice Chair for 2027, ensuring experie...
The FDA placed Bright Minds Biosciences' planned Phase 2 epilepsy trial for BMB-101 on partial clinical hold due to toxicity findings in mice and insufficient pharmacokinetic and juvenile-toxicity data. This action caused a sharp decline in the compa...
NEAR governance approved a plan to reduce the maximum annual issuance of the NEAR token from 2.5% to 1.6%. This change aims to slow the rate at which new tokens enter circulation, potentially impacting staking rewards by lowering them. The plan inclu...
